Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ZNTL Zentalis Pharmaceuticals

20.760
+0.050+0.24%
Trading Session 09/26 12:49 ET
High
21.670
Open
20.830
Turnover
4.01M
Low
20.570
Pre Close
20.710
Volume
190.80K
Market Cap
1.18B
P/E(TTM)
Loss
52wk High
87.190
Shares
56.98M
P/E(Static)
Loss
52wk Low
17.330
Float Cap
835.57M
Bid/Ask %
-20.00%
Historical High
87.190
Shs Float
40.25M
Volume Ratio
0.72
Historical Low
17.330
Dividend TTM
--
Div Yield TTM
--
P/B
2.50
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.47%
Amplitude
5.31%
Avg Price
21.001
Lot Size
1
Float Cap
835.57M
Bid/Ask %
-20.00%
Historical High
87.190
Shs Float
40.25M
Volume Ratio
0.72
Historical Low
17.330
Dividend TTM
--
P/B
2.50
Dividend LFY
--
Turnover Ratio
0.47%
Amplitude
5.31%
Avg Price
21.001
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
CEO: Dr. Kimberly Blackwell, M.D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...